SEC Form 4 · accession 0001209191-18-045799
U S PHYSICAL THERAPY INC /NV · USPH
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Christopher J Reading
Officer — Chief Executive Officer · Director
Period of report
Aug 6, 2018
Accepted (ET)
Aug 8, 2018 · 3:18 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000885978
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1,F2 | Aug 6, 2018 | S | 781 | $116.58 | D | 77,686 | D | |
| Common StockF3,F2 | Aug 7, 2018 | S | 451 | $115.78 | D | 77,235 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The price reported is a weighted average price. The shares were sold in multiple transactions at prices ranging from $116.50 - $117.35, both inclusive. The reporting person undertakes to provide to U.S. Physical Therapy, Inc., any of its shareholders or the staff of the Securities & Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.
- F2Includes 41,454 shares of restricted stock granted under the Company's equity plans. Restrictions lapse as to 6,206 shares on each of October 1, 2018 and January 1, 2019; 3,706 shares on each of April 1, 2019, July 1, 2019, October 1, 2019 and January 1, 2020: 2,286 shares on each of April 1, July 1 and October 1, 2020; 2,300 shares on January 1, 2021; and 1,265 shares on each of April 1, July 1 and October 1, 2021 and on January 1, 2022.
- F3The price reported is a weighted average price. The shares were sold in multiple transactions at prices ranging from $115.40 - $116.50, both inclusive. The reporting person undertakes to provide to U.S. Physical Therapy, Inc., any of its shareholders or the staff of the Securities & Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.